论文信息 - Long-term safety and overall survival update for BREAK-2, a phase 2, single-arm, open-label study of dabrafenib in previously treated metastatic melanoma (NCT01153763). - 字舞流文

Long-term safety and overall survival update for BREAK-2, a phase 2, single-arm, open-label study of dabrafenib in previously treated metastatic melanoma (NCT01153763).

D. Schadendorf | P. Ascierto | A. Ribas | E. Simeone | R. Swann | J. Grob | Kevin B. Kim | R. Kefford | C. Lebbé | L. Schuchter | O. Hamid | D. Minor | G. Aktan | U. Trefzer | A. Scheuber | T. Wilhelm | Anne O’Hagan